Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P24903

UPID:
CP2F1_HUMAN

ALTERNATIVE NAMES:
CYPIIF1

ALTERNATIVE UPACC:
P24903; A7KAU6; A7KAU7; A7KAU8; A7KAU9; A7KAV0; Q32MN5; Q8WWJ2

BACKGROUND:
The Cytochrome P450 2F1 enzyme, known as CYPIIF1, is integral to the metabolism of various toxic substances, including naphthalene. It possesses unique enzymatic activities, such as the dealkylation of ethoxycoumarin, propoxycoumarin, and pentoxyresorufin, while showing minimal activity towards ethoxyresorufin. Its role in the bioactivation of 3-methylindole (3MI) to 3-methylene-indolenine underscores its critical function in detoxification processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Cytochrome P450 2F1 offers a promising avenue for the development of novel therapeutic approaches. By elucidating its role in the detoxification of harmful substances, researchers can identify potential targets for drugs designed to prevent or treat conditions caused by pneumotoxicants.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.